Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 81

PubMed Links for Books (Select 3019694)

1.

Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial.

Kaplan SA, Schneider T, Foote JE, Guan Z, Carlsson M, Gong J.

BJU Int. 2011 May;107(9):1432-40. doi: 10.1111/j.1464-410X.2010.09640.x. Epub 2010 Sep 21.

PMID:
20860717
3.

Solifenacin for overactive bladder: secondary analysis of data from VENUS based on baseline continence status.

Toglia MR, Ostergard DR, Appell RA, Andoh M, Fakhoury A, Hussain IF.

Int Urogynecol J. 2010 Jul;21(7):847-54. doi: 10.1007/s00192-010-1120-6. Epub 2010 Mar 26.

PMID:
20339833
4.

Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.

Herschorn S, Swift S, Guan Z, Carlsson M, Morrow JD, Brodsky M, Gong J.

BJU Int. 2010 Jan;105(1):58-66. doi: 10.1111/j.1464-410X.2009.09086.x.

PMID:
20132103
5.

Trospium chloride and oxybutynin hydrochloride in a german study of adults with urinary urge incontinence: results of a 12-week, multicenter, randomized, double-blind, parallel-group, flexible-dose noninferiority trial.

Zellner M, Madersbacher H, Palmtag H, Stöhrer M, Bödeker RH; P195 Study Group.

Clin Ther. 2009 Nov;31(11):2519-39. doi: 10.1016/j.clinthera.2009.11.005.

PMID:
20109997
6.

Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder.

Dmochowski RR, Peters KM, Morrow JD, Guan Z, Gong J, Sun F, Siami P, Staskin DR.

Urology. 2010 Jan;75(1):62-8. doi: 10.1016/j.urology.2009.09.018. Epub 2009 Nov 22. Erratum in: Urology. 2010 Jun;75(6):1519. Urology. 2011 Jun;77(6):1513.

PMID:
19931895
7.

Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT - a double-blind, placebo-controlled trial.

Vardy MD, Mitcheson HD, Samuels TA, Wegenke JD, Forero-Schwanhaeuser S, Marshall TS, He W.

Int J Clin Pract. 2009 Dec;63(12):1702-14. doi: 10.1111/j.1742-1241.2009.02209.x.

PMID:
19930331
8.

Urinary urgency outcomes after propiverine treatment for an overactive bladder: the 'Propiverine study on overactive bladder including urgency data'.

Lee KS, Lee HW, Choo MS, Paick JS, Lee JG, Seo JT, Lee JZ, Lee YS, Yoon H, Park CH, Na YG, Jeong YB, Lee JB, Park WH.

BJU Int. 2010 Jun;105(11):1565-70. doi: 10.1111/j.1464-410X.2009.09050.x. Epub 2009 Nov 12.

PMID:
19912183
9.

Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trial.

Toglia MR, Serels SR, Laramée C, Karram MM, Nandy IM, Andoh M, Seifeldin R, Forero-Schwanhaeuser S.

Postgrad Med. 2009 Sep;121(5):151-8. doi: 10.3810/pgm.2009.09.2062.

PMID:
19820284
10.

Extended-release trospium chloride improves quality of life in overactive bladder.

Dmochowski RR, Rosenberg MT, Zinner NR, Staskin DR, Sand PK.

Value Health. 2010 Mar-Apr;13(2):251-7. doi: 10.1111/j.1524-4733.2009.00652.x. Epub 2009 Oct 8.

PMID:
19818062
11.

Trospium chloride extended release is effective and well tolerated in women with overactive bladder syndrome.

Sand PK, Dmochowski RR, Zinner NR, Staskin DR, Appell RA.

Int Urogynecol J Pelvic Floor Dysfunct. 2009 Dec;20(12):1431-8. doi: 10.1007/s00192-009-0969-8. Epub 2009 Aug 29.

PMID:
19727537
12.

Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.

Rogers RG, Bachmann G, Scarpero H, Jumadilova Z, Sun F, Morrow JD, Guan Z, Bavendam T.

Curr Med Res Opin. 2009 Sep;25(9):2159-65. doi: 10.1185/03007990903103279.

PMID:
19601704
13.

Efficacy and tolerability of fesoterodine in women with overactive bladder.

Sand PK, Morrow JD, Bavendam T, Creanga DL, Nitti VW.

Int Urogynecol J Pelvic Floor Dysfunct. 2009 Jul;20(7):827-35. doi: 10.1007/s00192-009-0857-2. Epub 2009 Mar 17.

PMID:
19495545
14.

Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study.

Malone-Lee JG, Al-Buheissi S.

BJU Int. 2009 Apr;103(7):931-7. doi: 10.1111/j.1464-410X.2009.08361.x. Epub 2009 Mar 5.

PMID:
19281469
15.

Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study.

Staskin DR, Dmochowski RR, Sand PK, Macdiarmid SA, Caramelli KE, Thomas H, Hoel G.

J Urol. 2009 Apr;181(4):1764-72. doi: 10.1016/j.juro.2008.11.125. Epub 2009 Feb 23.

PMID:
19233423
16.

Efficacy and safety of solifenacin succinate in Korean patients with overactive bladder: a randomised, prospective, double-blind, multicentre study.

Choo MS, Lee JZ, Lee JB, Kim YH, Jung HC, Lee KS, Kim JC, Seo JT, Paick JS, Kim HJ, Na YG, Lee JG.

Int J Clin Pract. 2008 Nov;62(11):1675-83. doi: 10.1111/j.1742-1241.2008.01898.x.

17.

Continued symptom improvement in sexually active women with overactive bladder and urgency urinary incontinence treated with tolterodine ER for 6 months.

Rogers RG, Omotosho T, Bachmann G, Sun F, Morrow JD.

Int Urogynecol J Pelvic Floor Dysfunct. 2009 Apr;20(4):381-5. doi: 10.1007/s00192-008-0782-9. Epub 2009 Jan 9.

PMID:
19132285
18.

Effects of tolterodine extended release on patient perception of bladder condition and overactive bladder symptoms*.

Herschorn S, Heesakkers J, Castro-Diaz D, Wang JT, Brodsky M, Guan Z; Disease Management Study Team.

Curr Med Res Opin. 2008 Dec;24(12):3513-21. doi: 10.1185/03007990802537122 .

PMID:
19032133
19.

Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial.

Karram MM, Toglia MR, Serels SR, Andoh M, Fakhoury A, Forero-Schwanhaeuser S.

Urology. 2009 Jan;73(1):14-8. doi: 10.1016/j.urology.2008.08.485. Epub 2008 Nov 8.

PMID:
18995887
20.

Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial.

Cardozo L, Hessdörfer E, Milani R, Arañó P, Dewilde L, Slack M, Drogendijk T, Wright M, Bolodeoku J; SUNRISE Study Group.

BJU Int. 2008 Nov;102(9):1120-7. doi: 10.1111/j.1464-410X.2008.07939.x. Epub 2008 Oct 6.

PMID:
18990175
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk